Wednesday, January 25, 2023 MA9 publication: Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Speers CW, Symmans WF, Barlow WE, Trevarton A, The S, Du L, Rae JM, Shak S, Baehner R, Sharma P, Pusztai L, Hortobagyi GN, Hayes DF, Albain KS, Godwin A, Thompson A. Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. J Clin Oncol 2023. https://ascopubs.org/doi/full/10.1200/JCO.22.01499?role=tab PURPOSE: Chemotherapy has not demonstrated benefit over adjuvant endocrine therapy alone for postmenopausal patients with node-positive breast cancer with a 21-gene breast recurrence score (RS) of 25 or below (RS ≤ 25). We tested whether combined results from RS and the sensitivity to endocrine therapy (SET2,3) index of endocrine-related transcription (SETER/PR) adjusted for baseline prognostic index (BPI) improve prognostic assessment, and whether SET2,3 predicted benefit from anthracycline-based chemotherapy. CONCLUSION: SET2,3 index was not correlated with RS, demonstrated additive prognostic performance, and was not chemopredictive in this subset of patients from S8814. The SETER/PR and BPI components of SET2,3 each added prognostic information to RS. MAC4-5 publication: Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winer EP, Ruepp B, Loi S, Coates AS, Gelber RD, Goldhirsch A, Regan MM, Francis PA. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials (ONLINE). J Clin Oncol 2022. https://doi.org/10.1200/JCO.22.01064 The combined analysis of SOFT-TEXT compared outcomes in 4,690 premenopausal women with estrogen/progesterone receptor–positive (ER/PgR+) early breast cancer randomly assigned to 5 years of exemestane + ovarian function suppression (OFS) versus tamoxifen + OFS. After a median follow-up of 9 years, exemestane + OFS significantly improved disease-free survival (DFS) and distant recurrence-free interval (DRFI), but not overall survival, compared with tamoxifen + OFS. We now report DFS, DRFI, and overall survival after a median follow-up of 13 years. EN10-EN11 publication: Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program RAINBO Research Consortium. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program (ONLINE). Int J Gynecol Cancer 33: 109, 2022. https://ijgc.bmj.com/content/33/1/109 RAINBO is an innovative practice-defining program consisting of three randomized clinical trials of novel adjuvant treatment strategies for women with high-risk p53abn endometrial cancer, MMRd endometrial cancer, and NSMP endometrial cancer and one clinical trial of treatment de-escalation for women with POLEmut endometrial cancer. In each trial, oncological outcomes, survival, toxicity, and quality of life will be uniformly registered to enable pooling for the overarching research program. As such, RAINBO will give a comprehensive answer to the question whether molecular-directed treatment is more effective, less toxic, and yields better quality of life than the current standard of care for women with endometrial cancer. CRC6 publication: Physical Activity in Stage III Colon Cancer Brown JC, Ma C, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Couture F, Kuebler P, Kumar P, Lewis D, Tan B, Krishnamurthi S, O'Reilly EM, Shields AF, Meyerhardt JA. Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). J Clin Oncol 41: 243-54, 2023. https://doi.org/10.1200/JCO.22.00171 PURPOSE - To determine the specific types, durations, and intensities of recreational physical activity associated with the greatest improvements in disease-free survival (DFS) of patients with colon cancer. CONCLUSION - Among patients with stage III colon cancer enrolled in a trial of postoperative treatment, larger volumes of recreational physical activity, longer durations of light- to moderate-intensity aerobic physical activity, or any vigorous-intensity aerobic physical activity were associated with the greatest improvements in DFS. General Review Publication: Reproductive Outcomes in Young Breast Cancer Survivors Treated (15-39) in Ontario, Canada Rushton M, Pudwell J, Wei X, Powell M, Richardson H, Velez MP. Reproductive Outcomes in Young Breast Cancer Survivors Treated (15-39) in Ontario, Canada. Curr Oncol 29: 8591-9, 2022. https://www.mdpi.com/1718-7729/29/11/677 Conclusions: This population-based cohort study found a significant association between chemotherapy treatment for AYA breast cancer and increased risk of Infertility and POI. There was also a novel finding that women with breast cancer who did not receive chemotherapy were also at a higher risk of Infertility and POI relative to women without cancer; an important detail to inform the care and counselling of AYA breast cancer patients. Further investigation into other mechanisms that can contribute to POI in women with breast cancer is needed. Oncofertility  is an important area which requires more attention to optimize care and education of young women with breast cancer.